Shares of Atyr Pharma Inc. (NASDAQ:LIFE) rose 16% on Wednesday . The stock traded as high as $3.04 and last traded at $3.04, with a volume of 313,064 shares trading hands. The stock had previously closed at $2.62.

LIFE has been the subject of several research analyst reports. Zacks Investment Research raised Atyr Pharma from a “sell” rating to a “buy” rating and set a $3.50 price objective for the company in a report on Tuesday, May 31st. BMO Capital Markets reissued a “hold” rating on shares of Atyr Pharma in a report on Thursday, May 12th. Finally, William Blair lowered Atyr Pharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 31st. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Atyr Pharma has an average rating of “Hold” and a consensus target price of $23.75.

The company’s 50-day moving average price is $2.92 and its 200 day moving average price is $4.20. The company’s market capitalization is $72.48 million.

Atyr Pharma (NASDAQ:LIFE) last released its quarterly earnings results on Wednesday, May 11th. The company reported ($0.68) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.70) by $0.02. Analysts predict that Atyr Pharma Inc. will post ($2.79) EPS for the current year.

In related news, insider Grove Matsuoka purchased 12,412 shares of the firm’s stock in a transaction dated Wednesday, May 11th. The shares were acquired at an average cost of $3.04 per share, with a total value of $37,732.48. Following the completion of the purchase, the insider now directly owns 2,412 shares of the company’s stock, valued at $7,332.48. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.